Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donor-derived CMVpp65-specific T cells
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived CMVpp65-specific T cells are an adoptive cellular immunotherapy developed by Peking University People's Hospital for the treatment and prevention of cytomegalovirus (CMV) infection in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), particularly haploidentical HSCT. These T cells are isolated or expanded from the original stem cell donor and are specifically reactive against the CMV pp65 antigen, a major structural protein of the virus. By infusing these virus-specific T cells (VSTs), the therapy aims to rapidly reconstitute the recipient's antiviral immunity, which is often severely compromised post-transplant, thereby clearing CMV viremia and preventing progression to CMV disease without the toxicities associated with traditional antiviral drugs like ganciclovir.
- Other names
- CMV-specific T cellsCMVpp65-specific T cellsCMVpp-65-specific T cellsCMVpp 65-specific T cellsPreemptive CMV-specific T cells
02
Targets
Cytomegalovirus phosphoprotein 65 peptide presented by human leukocyte antigen
Beyond the preview
Go deeper on Donor-derived CMVpp65-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Donor-derived CMVpp65-specific T cells.